Collins, Cathleen
Sharpe, Emily
Silber, Abigail
Kulke, Sarah
Hsieh, Elena W. Y.
Article History
Received: 4 January 2021
Accepted: 3 May 2021
First Online: 13 May 2021
Declarations
:
: Not applicable.
: All authors of this manuscript attest that we have all reviewed this manuscript and have contributed in a substantive and intellectual manner to the work described.
: Cathleen Collins, Emily Sharpe, Abigail Silber and Elena Hsieh receive consulting fees from Enzyvant Therapeutics. Sarah Kulke is Vice President of Medical Affairs at Enzyvant Therapeutics (since May 2020) and therefore receives salary, annual performance bonus, and cash based long term incentive program.